[go: up one dir, main page]

WO2001061360A3 - Methode d'identification - Google Patents

Methode d'identification Download PDF

Info

Publication number
WO2001061360A3
WO2001061360A3 PCT/GB2001/000693 GB0100693W WO0161360A3 WO 2001061360 A3 WO2001061360 A3 WO 2001061360A3 GB 0100693 W GB0100693 W GB 0100693W WO 0161360 A3 WO0161360 A3 WO 0161360A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpr
activity
identification
protein
gpr31
Prior art date
Application number
PCT/GB2001/000693
Other languages
English (en)
Other versions
WO2001061360A2 (fr
Inventor
Alan Wise
Original Assignee
Glaxo Group Ltd
Alan Wise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Alan Wise filed Critical Glaxo Group Ltd
Priority to AU33895/01A priority Critical patent/AU3389501A/en
Publication of WO2001061360A2 publication Critical patent/WO2001061360A2/fr
Publication of WO2001061360A3 publication Critical patent/WO2001061360A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé servant à identifier un agent modulant l'activité du récepteur 31 couplé à la protéine G (GPR 31). Ce procédé consiste à: (i) mettre en contact un agent d'essai avec GPR 31 ou une de ses variantes capable de se coupler à une protéine G et (ii) contrôler l'activité de GPR 31 en présence d'une protéine G, ce qui permet de déterminer si l'agent d'essai module l'activité de GPR 31. L'invention concerne également des activateurs de GPR 31, des inhibiteurs de lipolyse et de polynucléotide GPR 31 qu'on peut utiliser pour traiter la dyslipidémie, la maladie cardiaque coronarienne, l'athérosclérose, la thrombose ou l'obésité, l'angine, la défaillance rénale chronique, la maladie vasculaire périphérique, les attaques, le diabète de type I ou le syndrome métabolique (syndrome X).
PCT/GB2001/000693 2000-02-18 2001-02-19 Methode d'identification WO2001061360A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33895/01A AU3389501A (en) 2000-02-18 2001-02-19 Assay

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0003898.4 2000-02-18
GBGB0003898.4A GB0003898D0 (en) 2000-02-18 2000-02-18 Assay

Publications (2)

Publication Number Publication Date
WO2001061360A2 WO2001061360A2 (fr) 2001-08-23
WO2001061360A3 true WO2001061360A3 (fr) 2002-03-28

Family

ID=9885980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000693 WO2001061360A2 (fr) 2000-02-18 2001-02-19 Methode d'identification

Country Status (3)

Country Link
AU (1) AU3389501A (fr)
GB (1) GB0003898D0 (fr)
WO (1) WO2001061360A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254224A1 (en) * 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
WO2005059561A2 (fr) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 31 (gpr31)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022129A1 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs couples a la proteine g humaine non endogenes et actives de façon constitutive

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022129A1 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs couples a la proteine g humaine non endogenes et actives de façon constitutive

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 21 August 2000 (2000-08-21), BEHAN D P ET AL: "Non-endogenous constitutively activated human G protein-coupled receptors, useful for identifying agonists for use as pharmaceutical agents", XP002174049 *
SOEDER KURT J ET AL: "The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 12017 - 12022, XP002174047, ISSN: 0021-9258 *
WALSTON J ET AL: "The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 188, no. 2, 1 April 1997 (1997-04-01), pages 207 - 213, XP004059301, ISSN: 0378-1119 *
ZINGONI ALESSANDRA ET AL: "Isolation and chromosomal localization of GPR31, a human gene encoding a putative G protein-coupled receptor.", GENOMICS, vol. 42, no. 3, 1997, pages 519 - 523, XP002174048, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
AU3389501A (en) 2001-08-27
GB0003898D0 (en) 2000-04-05
WO2001061360A2 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
DeQuattro et al. Neurogenic factors in human hypertension: mechanism or myth?
Keane et al. Neuropeptide Y, B‐type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein‐α
DE69735127D1 (de) Enzymsensor
Kim et al. High-sensitivity detection for model organophosphorus and carbamate pesticide with quartz crystal microbalance-precipitation sensor
WO2001061359A3 (fr) Dosage biologique
WO2008041953A3 (fr) Diagnostic et traitement de la dingue
AU2001291538A1 (en) Method and apparatus for estimating systolic and mean pulmonary artery pressuresof a patient
WO2002066981A3 (fr) Procede de surveillance de la coagulabilite et des etats d'hypercoagulabilite
ATE331960T1 (de) Diagnose von myokardinfarkt und akutem koronarsyndrom durch kombination von markern
IS2793B (is) Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A afsýringarkljúfshindrum til framleiðslunnar á lyfi til að meðhöndla sykursýkitaugakvilla
WO2007008590A3 (fr) Capture et agregation repartie d'informations d'utilisation d'application dynamique
FR2818506B1 (fr) Chaussure
DE60137346D1 (de) Rechnerverfahren und -system zum ausführen von java-rechnerprogrammen
WO2001061360A3 (fr) Methode d'identification
DE602007001467D1 (de) Therapeutische Zubereitung von hochreinem FVIIa und Verfahren zu dessen Gewinnung
DE60238699D1 (de) Mehrfachanalytassay-vorrichtung mit multi-spot-nachweiszone
SE0103072D0 (sv) Multi-analyte assay device with multi-spot detection zone
WO2001044497A3 (fr) Regulation de la proteine kinase
EP1293779A3 (fr) Surface de biocapteur
ATE503021T1 (de) Verfahren zum nachweis von endoglykosidase aktivität
AR037870A1 (es) Metodo para determinar la actividad biologica de defibrotida
ATE15387T1 (de) Verfahren zum bestimmen von enzym-inhibitorkomplexen.
US10426998B1 (en) Portable device for movement and resistance training of the lower extremities
AU2001274562A1 (en) Ligand to gpr8 and dna thereof
ATE279924T1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5- dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP